The 1.6 million (just in the US!) sufferers of atopic dermatitis, a type of eczema, will no doubt be thrilled at the results of two Phase III trials released Saturday. The biologic treatment dupilumab was shown to drastically reduce the amount and severity of inflammation caused by the skin condition, with close to 40% of those receiving the drug reporting a complete disappearance of rashes. This is a huge deal, considering the condition seems to be otherwise untreatable. The FDA agrees, and assigned the treatment a Breakthrough Therapy designation in 2014 after positive Phase I and II results, meaning we could see an approval from them as early as March of next year.